Development of Organometallic Ruthenium(II) Anticancer (RAPTA) Drugs

Authors

  • Wee Han Ang

DOI:

https://doi.org/10.2533/chimia.2007.140

Keywords:

Anticancer drugs, Antitumour, Chemotherapy, Metallopharmaceuticals, Ruthenium

Abstract

The systematic development of the RAPTA family of organometallic ruthenium(II) anticancer drugs containing a monodentate 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane (pta) ligand and a ?6-arene ligand is described.

Downloads

Published

2007-04-25

How to Cite

[1]
W. H. Ang, Chimia 2007, 61, 140, DOI: 10.2533/chimia.2007.140.

Issue

Vol. 61 No. 4 (2007): Laureates: Awards and Honors Swiss Chemical Society, Fall Meeting 2006

Section

Scientific Articles

License

Copyright (c) 2007 Swiss Chemical Society

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.